An investigational medicine called zuranolone has generated significant, rapid, and enduring symptom reduction in women with postpartum depression. The drug was compared with placebo in a phase 3…
Read More
Is it possible to disrupt the process by which a mother can transmit risk for psychiatric disorders to her offspring? New research suggests one way in which this may be possible.
Read More
Past research has established a clear connection between maternal depression and risk of adverse outcomes in newborns, for instance a higher risk of the child having low birthweight. Over the longer…
Read More
On March 19, 2019, the U.S. Food and Drug Administration approved the first-ever drug specifically designed to alleviate the symptoms of postpartum depression. The drug, called brexanolone, acts…
Read More
During pregnancy and for some time after giving birth, a woman’s immune response in the brain may be tuned down, a new study in rats suggests. This research was published in the November 2017 issue…
Read More
